Astellas Pharma Overview

  • Founded
  • 1923
Founded
  • Status
  • Public
  • Employees
  • 15,455
Employees
  • Stock Symbol
  • 4503
Stock Symbol
  • Investments
  • 29
  • Share Price
  • $16.01
  • (As of Thursday Closing)

Astellas Pharma General Information

Description

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Contact Information

Formerly Known As
Fujisawa Pharmaceutical, Yamanouchi Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
TKS
Primary Office
  • 2-5-1, Nihonbashi-Honcho
  • Chuo-ku
  • Tokyo, 103-8411
  • Japan
+81 00-0000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Astellas Pharma Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.01 $15.79 $14.59 - $18.27 $29.4B 1.83B 5.63M $0.59

Astellas Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019
EV 29,966,509 29,259,967 27,636,821 25,970,880
Revenue 11,846,531 11,783,609 11,963,701 11,782,368
EBITDA 2,031,764 1,968,163 2,854,593 2,772,259
Net Income 1,094,278 1,137,208 1,797,172 2,004,679
Total Assets 20,476,445 20,610,210 21,422,259 17,114,508
Total Debt 2,696,109 3,147,188 4,394,981 604,422
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Astellas Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Astellas Pharma‘s full profile, request access.

Request a free trial

Astellas Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majori
Pharmaceuticals
Tokyo, Japan
15,455 As of 2021
00000000000

00000 00

t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labor
000000000000000
Ahmedabad, India
00000 As of 0000
000.00
0.00 0000-00-00
00000000000 000.00

00000000

te irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exce
000000000000000
Hyderabad, India
00000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Astellas Pharma Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intas Pharmaceuticals Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
000000000 000000 Corporation Hyderabad, India 00000 00000 000000000 00000
000 000000 Corporate Backed or Acquired Monheim, Germany 0000 000000&0
000000000 Corporation Mumbai, India 0000 000000000
000000 Formerly PE-Backed Bangalore, India 00000 000.00 00000000 000.00
You’re viewing 5 of 36 competitors. Get the full list »

Astellas Pharma Patents

Astellas Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020283372-A1 Method for treating muscular dystrophy by targeting dmpk gene Pending 28-May-2019 0000000000000
US-20210355464-A1 Method for treating muscular dystrophy by targeting utrophin gene Pending 16-Nov-2018 0000000000
AU-2019381460-A1 Method for treating muscular dystrophy by targeting utrophin gene Pending 16-Nov-2018 0000000000
EP-3880255-A1 Method for treating muscular dystrophy by targeting utrophin gene Pending 16-Nov-2018 00000000000
CA-3119618-A1 Method for treating muscular dystrophy by targeting utrophin gene Pending 16-Nov-2018 C12N15/113
To view Astellas Pharma’s complete patent history, request access »

Astellas Pharma Executive Team (26)

Name Title Board Seat Contact Info
Kenji Yasukawa Ph.D Chief Executive Officer & Board Member
Masao Yoshida Chief Executive Officer, Astellas Pharma Europe
Yoshitsugu Shitaka Chief Scientific Officer & President of Drug Discovery Research
Seigo Kashi President
Naoki Okamura Chief Financial Officer, Finance & Board Member
You’re viewing 5 of 26 executive team members. Get the full list »

Astellas Pharma Board Members (8)

Name Representing Role Since
000000 000000000 Astellas Pharma Board Member 000 0000
00000 00000000 00.0 Astellas Pharma Chief Executive Officer & Board Member 000 0000
00000 0000000 Astellas Pharma Chief Financial Officer, Finance & Board Member 000 0000
00000 000000000 Astellas Pharma Board Member 000 0000
0000000 000000 Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Astellas Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Astellas Pharma Investments & Acquisitions (29)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 18-Dec-2020 0000000000 Pharmaceuticals
00000 0000000 21-Apr-2020 0000000000 000.00 Drug Discovery 00000 000
00000000 0000 15-Jan-2020 0000000000 00.000 Biotechnology 00000 000
000000 000000 26-Dec-2019 0000000000 00000 Biotechnology 00000 000
ARCHES Technology 28-Oct-2019 Grant 0000 Enterprise Systems (Healthcare)
You’re viewing 5 of 29 investments and acquisitions. Get the full list »

Astellas Pharma Subsidiaries (11)

Company Name Industry Location Founded
Xyphos Biosciences Biotechnology South San Francisco, CA 2017
0000000 0000000000 Biotechnology Cambridge, MA 0000
000000000 00000 Biotechnology Seattle, WA 0000
00000 000000000000 Drug Discovery Cambridge, United Kingdom 0000
00000000 000000000 Biotechnology San Francisco, CA 0000
You’re viewing 5 of 11 subsidiaries. Get the full list »

Astellas Pharma Exits (6)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 000 02-Jun-2015 00000 00000 00 000.00 Completed
  • 5 buyers
000000 000 29-May-2015 00000 0000000 00000 Completed
  • 2 buyers
00000 00000000 000 01-Oct-2013 00000 0000000 Completed
  • 2 buyers
0000000 (000000000 22-Jun-2009 000000000 00000 00 0000 Completed
  • 00000000 000000
FibroGen 10-Jan-2007 Later Stage VC 0000 Completed
  • 2 buyers
You’re viewing 5 of 6 exits. Get the full list »